Prime Medicine, Inc. (PRME) Stock Price & Analysis
Prime Medicine, Inc. (PRME) fell 0.67% to USD 2.95 as of July 25, 2026 at 16:28 UTC, according to Nexqual real-time market data.
PRME last closed at USD 2.97; the session ranged USD 2.86–3.03 on volume of 2,354,953 shares. Market capitalization is $532.82M, with a 52-week range of USD 2.67–6.94 (NGM). Source: Nexqual, July 25, 2026 at 16:28 UTC.
Key Statistics (as of July 25, 2026 at 16:28 UTC)
| Price | USD 2.95 |
|---|---|
| Change | ▼ 0.67% (down) |
| Previous Close | USD 2.97 |
| Open | USD 3 |
| Day Range | USD 2.86 – 3.03 |
| 52-Week Range | USD 2.67 – 6.94 |
| Volume | 2,354,953 shares |
| Market Cap | $532.82M |
| Exchange | NGM |
Technical Analysis (PRME)
Nexqual's technical model rates PRME "SELL" based on 1 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 16:28 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 39.25 (neutral) |
| vs SMA50 | Below (USD 3.27) |
| MACD | -0.1 (negative) |
Analyst Ratings (PRME)
Wall Street analysts rate PRME "Buy" based on 10 analysts, with a mean price target of USD 7.12 (range USD 4.25–11), per Nexqual as of July 25, 2026 at 16:28 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 10 |
| Mean Target | USD 7.12 |
| High Target | USD 11 |
| Low Target | USD 4.25 |
| Buy / Hold / Sell | 10 / 3 / 0 |
Earnings (PRME)
| Next Earnings Date | 2026-08-06 |
|---|---|
| EPS Estimate | USD -0.26 |
| Revenue Estimate | $1.11M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.28 vs est -0.25 ▼ miss |
| 2025-12-31 | USD -0.24 vs est -0.26 ▲ beat |
| 2025-09-30 | USD -0.32 vs est -0.25 ▼ miss |
| 2025-06-30 | USD -0.41 vs est -0.34 ▼ miss |
Source: Nexqual, July 25, 2026 at 16:28 UTC.
Financials & Fundamentals (PRME)
| Total Revenue | $4.03M |
|---|---|
| Revenue Growth (YoY) | -41.10% |
| Gross Margin | +0.00% |
| Operating Margin | -5917.52% |
| Profit Margin | +0.00% |
| ROE | -216.06% |
| Debt / Equity | 149.3 |
| Current Ratio | 3.8 |
| Total Cash | $135.50M |
| Total Debt | $114.51M |
| Free Cash Flow | $-78.32M |
Source: Nexqual, July 25, 2026 at 16:28 UTC.
Financial Health Score (PRME)
Nexqual rates Prime Medicine, Inc.'s overall financial health "Weak" across five dimensions, as of July 25, 2026 at 16:28 UTC.
| Growth | Strong — Revenue +55% YoY (annual) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $135M cash vs $115M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$78M, burning cash |
| Efficiency | Critical — ROE -216%, ROA -41.5% |
Ownership (PRME)
| Insider Ownership | +23.76% |
|---|---|
| Institutional Ownership | +66.68% |
| Shares Outstanding | 180.62M |
| Float | 114.96M |
| Short % of Float | +23.76% |
Source: Nexqual, July 25, 2026 at 16:28 UTC.
Leadership (PRME)
Prime Medicine, Inc. is led by Allan Reine (age 50), CEO & Director, per Nexqual as of July 25, 2026 at 16:28 UTC.
| CEO & Director | Allan Reine (age 50) |
|---|---|
| Chief Financial Officer | Svetlana Makhni (age 41) |
Major Backers & Investors (PRME)
Notable institutional backers of Prime Medicine, Inc. include Alphabet Inc., ARK Invest, T. Rowe Price, according to Nexqual as of July 25, 2026 at 16:28 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Alphabet Inc. | 9.17% |
| ARK Invest | 7.5% |
| T. Rowe Price | 4.56% |
| Balyasny Asset Management LP | 2.28% |
| Casdin Capital, LLC | 1.75% |
| Woodline Partners LP | 1.66% |
| Amova Asset Management Americas Inc | 1.63% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| State Street | 6.39% |
| BlackRock | 6.07% |
| Vanguard Group | 4.9% |
Source: Nexqual, July 25, 2026 at 16:28 UTC.
From Prime Medicine, Inc.'s Latest SEC 10-K Filing (filed 2026-03-03)
Key Strengths & Strategy (as disclosed to the SEC)
- Prime Editing Platform Architecture The core components of our platform include the Prime Editor enzyme, pegRNAs, and delivery vehicles.
- We expect our focus on liver-directed in vivo editing, combined with the modularity of our platform, will allow us to build a pipeline with breadth and depth while maintaining operational efficiency and disciplined capital deployment.
- Our approach is grounded in Prime Editing, a next-generation gene editing technology that enables targeted modifications to genomic DNA without introducing double-stranded breaks.
- We believe Prime Editing represents the most versatile and precise method for rewriting, replacing, or repairing DNA sequences and may allow us to address a broad spectrum of diseases with an improved safety and specificity profile relative to earlier editing technologies.
Partnerships
- We received a $55.0 million upfront payment under the BMS Collaboration Agreement and a $55.0 million equity investment under a Securities Purchase Agreement with BMS.
- Cystic Fibrosis Foundation 2024 Agreement In January 2024, we entered into an agreement with CFF, or the 2024 CFF Agreement, under which CFF agreed to provide up to $15.0 million, payable in multiple tranches, to support the development of Prime Editors for the 7 treatment of CF.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CRBU | Caribou Biosciences, Inc. | USD 1.57 | ▼ 5.42% |
| SANA | Sana Biotechnology, Inc. | USD 3.18 | ▲ 1.92% |
| ABSI | Absci Corporation | USD 7.56 | ▼ 8.25% |
| BEAM | Beam Therapeutics Inc. | USD 25.1 | ▼ 5.78% |
| NRIX | Nurix Therapeutics, Inc. | USD 23.38 | ▼ 0.93% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 16:28 UTC. This page is informational and not investment advice.